EcoDrugPlus

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSOMYG00000035762
Gene Symbol: MAPK8A
1 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSOMYG00000011169
Gene Symbol: MAPK8A
1 Cross references
215 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSOMYG00000032860
Gene Symbol: MAPK8B
1 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSOMYG00000044519
Gene Symbol: MAPK8B
1 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSOMYG00000070762
Gene Symbol: MAP2K1
2 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2a

Ensembl ID : ENSOMYG00000026830
Gene Symbol: MAP2K2A
1 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSOMYG00000020235
Gene Symbol: MAP2K2B
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSOMYG00000019038
Gene Symbol: MAP2K2B
1 Cross references
194 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSOMYG00000031418
Gene Symbol: MAP3K1
1 Cross references
155 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSOMYG00000020429
Gene Symbol: MAP3K10
1 Cross references
176 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOMYG00000030167
Gene Symbol: MAP3K12
1 Cross references
179 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSOMYG00000044128
Gene Symbol: MAP3K12
1 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).